Cardio Vascu-Grow improves wound healing in diabetes

The pre-clinical data suggests that Cardio Vascu-Grow significantly improves the healing rate of open wounds in a diabetic rodent model. Dr Jack Jacobs, CEO of Cardio said: “At defined times, up to a six-fold increase in the healing rate was observed. These statistically significant results are very encouraging and support my hope that this drug candidate could improve the lives of millions of diabetics and elderly people.”

The protein drug works by promoting the growth of new blood vessels in the skin, aiding blood perfusion, which in turn helps damaged tissue heal. The drug has already undergone clinical trials in humans as a treatment for coronary artery disease. The company has also received positive results from pre-clinical studies assessing the drug’s ability to minimize the area of the brain affected by stroke. Cardio continues to pursue the drug’s development in the areas of stroke, heart disease and diabetic wounds.

The president of Cardio, Daniel Montano commented: “For millions of Americans and Europeans, open sores for the elderly, diabetic leg sores and bedsores are serious medical issues. If the pre-clinical results we have obtained in animals remain constant in humans, I believe our protein drug candidate could reduce pain and suffering for these people, and dramatically lower the cost of treating diabetics and the elderly.”

The market for wound healing includes diabetic, bedridden and elderly patients that suffer from wounds, open sores and diabetic ulcers. According to the US Healthcare Finance Administration, approximately two and a half to three million patients a year suffer from these maladies. Annual treatment costs in the US alone are in the range of $5-7 billion.